Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  2. Drug

    Quinine

    go.drugbank.com/drugs/DB00468
    ApprovedInvestigational

    Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. … It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis.

  3. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  4. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    [L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585] … Zapomeran, marketed under the brand name Kostaive (ARCT-154), is a self-amplifying mRNA COVID-19 vaccine for individuals 18 years and older.

  5. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa).

    Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL
  6. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment. … [L63806,L63934] Established ADHD pharmacotherapy acts on norepinephrine and dopamine without a serotonergic component, and Otsuka describes centanafadine as the first and only approved norepinephrine-dopamine-serotonin

  7. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.

    Synonyms: N,2-Dimethyl-2-phenylsuccinimide, alpha-Methyl-alpha-phenyl N-methyl succinimide
  8. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.

  9. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three … Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class.

  10. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. … [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections.

    Synonyms: -Amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl)-7-([(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene